The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study trial provided evidence that targeting IL-1β with canakinumab (150 mg every 3 months) was associated with significant lower incidence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death (hazard ratio versus placebo, 0.85, p = 0.02) (203). This evidence concerns the gene IL1B and stroke disorder.